Form 4: Acrivon Therapeutics COO Exercises Stock Options
SEC Form 4 Filing
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, exercised stock options to acquire 10,000 shares of common stock at $1.04 per share on May 17, 2024.
Summary
- On May 17, 2024, Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, exercised stock options to purchase 10,000 shares of common stock at a price of $1.04 per share.
- Following this transaction, Devroe directly owns 69,097 shares of common stock.
- Devroe also holds options to purchase 86,615 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports a standard transaction of stock option exercise.
Industry Context
This is a routine disclosure of stock option exercise by a company executive, which is common in publicly traded companies as part of their compensation packages.
Stakeholder Impact
- The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares.
Key Dates
| Date | Description |
|---|---|
| 10/05/2021 | 25% of the shares subject to the option vested. |
| 01/13/2031 | Expiration date of the stock options. |
| 05/17/2024 | Date of transaction: Eric Devroe exercised stock options. |
| 05/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.